Literature DB >> 24495592

Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.

Toshihiko Iuchi1, Kazuo Hatano2, Takashi Kodama2, Tsukasa Sakaida3, Sana Yokoi4, Koichiro Kawasaki3, Yuzo Hasegawa3, Ryusuke Hara2.   

Abstract

PURPOSE/
OBJECTIVES: To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM). METHODS AND MATERIALS: All patients underwent postsurgical hypofractionated high-dose IMRT. Three layered planning target volumes (PTVs) were contoured. PTV1 was the surgical cavity and residual tumor on T1-weighted magnetic resonance images with 5-mm margins, PTV2 was the area with 15-mm margins surrounding the PTV1, and PTV3 was the high-intensity area on fluid-attenuated inversion recovery images. Irradiation was performed in 8 fractions at total doses of 68, 40, and 32 Gy for PTV1, PTV2, and PTV3, respectively. Concurrent TMZ was given at 75 mg/m(2)/day for 42 consecutive days. Adjuvant TMZ was given at 150 to 200 mg/m(2)/day for 5 days every 28 days. Overall and progression-free survivals were evaluated.
RESULTS: No acute IMRT-related toxicity was observed. The dominant posttreatment failure pattern was dissemination. During a median follow-up time of 16.3 months (range, 4.3-80.8 months) for all patients and 23.7 months (range, 12.4-80.8 months) for living patients, the median overall survival was 20.0 months after treatment. Radiation necrosis was diagnosed in 20 patients and was observed not only in the high-dose field but also in the subventricular zone (SVZ). Necrosis in the SVZ was significantly correlated with prolonged survival (hazard ratio, 4.08; P=.007) but caused deterioration in the performance status of long-term survivors.
CONCLUSIONS: Hypofractionated high-dose IMRT with concurrent and adjuvant TMZ altered the dominant failure pattern from localized to disseminated and prolonged the survival of patients with GBM. Necrosis in the SVZ was associated with better patient survival, but the benefit of radiation to this area remains controversial.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24495592     DOI: 10.1016/j.ijrobp.2013.12.011

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

Review 1.  New Hypofractionation Radiation Strategies for Glioblastoma.

Authors:  Melissa Azoulay; Jennifer Shah; Erqi Pollom; Scott G Soltys
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Should the subventricular zone be part of the "rad" zone?

Authors:  Benjamin W Corn; Jeffrey Raizer; Andrew A Kanner
Journal:  J Neurooncol       Date:  2014-05-23       Impact factor: 4.130

3.  A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.

Authors:  Melissa Azoulay; Steven D Chang; Iris C Gibbs; Steven L Hancock; Erqi L Pollom; Griffith R Harsh; John R Adler; Ciara Harraher; Gordon Li; Melanie Hayden Gephart; Seema Nagpal; Reena P Thomas; Lawrence D Recht; Lisa R Jacobs; Leslie A Modlin; Jacob Wynne; Kira Seiger; Dylann Fujimoto; Melissa Usoz; Rie von Eyben; Clara Y H Choi; Scott G Soltys
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 4.  Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma.

Authors:  Andrew W Smith; Minesh P Mehta; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2016-04-23       Impact factor: 4.130

Review 5.  Space Invaders: Brain Tumor Exploitation of the Stem Cell Niche.

Authors:  Justine Sinnaeve; Bret C Mobley; Rebecca A Ihrie
Journal:  Am J Pathol       Date:  2017-10-10       Impact factor: 4.307

6.  Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma.

Authors:  Natsuko Kondo; Rolf F Barth; Shin-Ichi Miyatake; Shinji Kawabata; Minoru Suzuki; Koji Ono; Norman L Lehman
Journal:  J Neurooncol       Date:  2017-05-22       Impact factor: 4.130

Review 7.  Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective.

Authors:  Katsumasa Nakamura; Tomonari Sasaki; Saiji Ohga; Tadamasa Yoshitake; Kotaro Terashima; Kaori Asai; Keiji Matsumoto; Yoshiyuki Shioyama; Hiroshi Honda
Journal:  Int J Clin Oncol       Date:  2014-07-02       Impact factor: 3.402

8.  Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma.

Authors:  Brent D Weinberg; Lauren Boreta; Steve Braunstein; Soonmee Cha
Journal:  J Neurooncol       Date:  2018-03-15       Impact factor: 4.130

9.  Hypofractionated radiation therapy with temozolomide versus standard chemoradiation in patients with glioblastoma multiforme (GBM): A prospective, single institution experience.

Authors:  Amal Rayan; Samya Abdel-Kareem; Huda Hasan; Asmaa M Zahran; Doaa A Gamal
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-25

10.  Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM.

Authors:  Angela Jia; Susan C Pannullo; Shlomo Minkowitz; Shoshana Taube; Jenghwa Chang; Bhupesh Parashar; Paul Christos; A Gabriella Wernicke
Journal:  Cureus       Date:  2016-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.